Clinical Trials Logo

Filter by:
NCT ID: NCT00688376 Completed - Clinical trials for Attention Impairment

Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment

Start date: July 2, 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy, safety and tolerability of donepezil in children with persistent attention impairment that is present at least 12 months after the completion of cancer treatment.

NCT ID: NCT00686959 Completed - Clinical trials for Non Small Cell Lung Cancer

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

PROCLAIM
Start date: September 2008
Phase: Phase 3
Study type: Interventional

This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.

NCT ID: NCT00684229 Withdrawn - Colon Cancer Clinical Trials

Regional Anesthesia in Colon Rectal Surgery

Start date: December 2007
Phase: N/A
Study type: Interventional

This study will compare recurrence rates in patients with colorectal cancer who will be randomly assigned to epidural anesthesia/analgesia combined with general anesthesia or to general anesthesia followed by opioid analgesia.

NCT ID: NCT00684177 Completed - Clinical trials for Skin Infections, Bacterial

Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)

Start date: May 2008
Phase: Phase 3
Study type: Interventional

The purpose of Study TOC110977 is to demonstrate clinical superiority of Retapamulin ointment, 1%, over placebo in patients with secondarily-infected traumatic lesions, which includes secondarily-infected lacerations, abrasions and sutured wounds. Subjects 2 months of age and older will be treated with topical retapamulin or placebo ointment twice daily for 5 days. The primary endpoint of this study is the clinical response at follow-up (Day 12-14; 7-9 days after the end of therapy) in the intent-to-treat clinical population.

NCT ID: NCT00683878 Completed - Type 2 Diabetes Clinical Trials

Add-on to Thiazolidinedione (TZD) Failures

Start date: July 2008
Phase: Phase 3
Study type: Interventional

The purpose of this clinical research study is to learn if BMS-512148 (Dapagliflozin) can help reduce the blood sugar levels in subjects with Type 2 Diabetes who are not well controlled on TZD alone. The safety of this treatment will also be studied

NCT ID: NCT00683657 Completed - Type 2 Diabetes Clinical Trials

Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone

Start date: July 2008
Phase: Phase 3
Study type: Interventional

This protocol will compare 24 hour glucose control for subject taking saxagliptin and metformin extended release (XR) versus metformin XR alone

NCT ID: NCT00683306 Approved for marketing - Clinical trials for Non Small Cell Lung Cancer (NSCLC)

Open Label Extension Study With Gefitinib (IRESSAâ„¢) for Completing Trial Patients Who May Benefit From Further Treatment

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide gefitinib treatment to patients who, on completion or closure of other gefitinib clinical studies, were either receiving placebo treatment, or are continuing on the same dose and regimen of gefitinib established in their preceding study, for as long as the patients continue to derive benefit.

NCT ID: NCT00682994 Completed - Advanced Cancer Clinical Trials

Patient and Family Decision Making in the Palliative Care Setting

Start date: March 2008
Phase: N/A
Study type: Interventional

The goal of this research study is to learn about any differences in certain health-related preferences between patients with cancer and their families. The main preferences being studied are how decisions are made about healthcare, as well as how much information people want to know about cancer. Specifically, researchers will compare questionnaire and interview data from Hispanic-Americans living in the United States (the M. D. Anderson part of this multicenter study) with Hispanics living in Latin America (in particular, Argentina, Chile, and Guatemala).

NCT ID: NCT00680901 Active, not recruiting - Clinical trials for Neoplasms, Gastrointestinal Tract

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Start date: June 4, 2008
Phase: Phase 3
Study type: Interventional

This is an international multi-center trial that will enroll patients with locally advanced, unresectable, or metastatic gastric, esophageal, or gastro-esophageal junction cancer whose tumors have amplification of the ErbB2 (HER2) gene. The trial will investigate whether lapatinib, when added to the chemotherapy regimen, capecitabine plus oxaliplatin (CapeOx), extends the time to progression and overall survival. Tumor ErbB2 (HER2) status must be known before trial entry. CapeOx is administered to all patients, and patients will be randomly assigned to receive either lapatinib or placebo.

NCT ID: NCT00680563 Terminated - Anemia Clinical Trials

A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.

Start date: April 2009
Phase: Phase 3
Study type: Interventional

This single arm study will assess the efficacy and safety of subcutaneous Mircera for the correction and maintenance of hemoglobin levels in predialysis patients with renal anemia who are not currently treated with ESA. Eligible patients will receive monthly subcutaneous injections at an initial recommended dose of 1.2 micrograms/kg. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.